Annual report
4543.TEDINET S100YGMG
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.13T | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.04T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥921.9bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥176.3bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥157.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥178.3bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥154.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥140.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥135.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥117.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥106.4bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥135.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥117.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥2.31T | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.83T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.83T | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.60T | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.47T | at 2022-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥727.7bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥459.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.58T | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.37T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.33T | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥1.58T | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.37T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.33T | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.11T | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.01T | at 2022-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥280.5bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥221.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥205.3bn | at 2022-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥230.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥210.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥146.3bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥344.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥82.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.5bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥155.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥108.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥62.1bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥92.14 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥79.01 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.5 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥59.5 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥58.72 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥92.12 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥78.99 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥71.47 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥59.48 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥58.69 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,074.18 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥927.85 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥893.8 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥746.07 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥669.23 | at 2022-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 68.5% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.8% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.5% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 9.2% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.7% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.4% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.5% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 31,185 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 30,689 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 30,591 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 30,207 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 28,294 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥452.2bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥428.7bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥399.8bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥375.0bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥341.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥100.9bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥89.4bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥174.5bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥147.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥110.7bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥91.1bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥79.4bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥198.1bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥148.3bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥158.9bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥122.3bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥87.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥79.0bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥62.8bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.58T | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥1.42T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥1.44T | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.33T | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.28T | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥597.1bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥549.7bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥987.5bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥870.0bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥813.8bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥765.6bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥765.4bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥88.5bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥69.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥107.75 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.58 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.05 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.61 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.52 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥107.72 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥82.56 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.03 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥52.59 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥41.49 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥30 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥44 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥34 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥669.07 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥589.54 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥547.68 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥513.67 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥505.54 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 62.3% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.2% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.6% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.6% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 17.1% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.5% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.3% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,480,559,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,480,559,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 745,348,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 747,682,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 5,736 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 5,633 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 5,554 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 5,457 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 5,377 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥924m |
| Reconciling Itemsreconciling | revenue external | 2025-04-01 → 2026-03-31 | ¥294m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥1.5bn |
| Blood And Cell Technologies Companyreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥21.7bn |
| Blood And Cell Technologies Companyreportable segment | employees | at 2026-03-31 | 6557 pure |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥231.0bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥33.6bn |
| Cardiac And Vascular Companyreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥36.7bn |
| Cardiac And Vascular Companyreportable segment | employees | at 2026-03-31 | 17007 pure |
| Cardiac And Vascular Companyreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥676.4bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥164.0bn |
| Medical Care Solutions Companyreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥36.7bn |
| Medical Care Solutions Companyreportable segment | employees | at 2026-03-31 | 6331 pure |
| Medical Care Solutions Companyreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥216.1bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥21.6bn |
| Terumo Organ Technologiesreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥1.1bn |
| Terumo Organ Technologiesreportable segment | employees | at 2026-03-31 | 238 pure |
| Terumo Organ Technologiesreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥8.0bn |
| Terumo Organ Technologiesreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.7bn |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥96.2bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥1.13T |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥220.9bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2025-03-31 | ¥298m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥712m |
| Blood And Cell Technologies Companyreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥17.8bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥200.3bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥26.5bn |
| Cardiac And Vascular Companyreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥43.6bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥624.4bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥154.7bn |
| Medical Care Solutions Companyreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥18.5bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥211.2bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥23.0bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥79.8bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥1.04T |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥204.2bn |
| Blood And Cell Technologies Companyreportable segment | employees | at 2026-03-31 | 287 pure |
| Cardiac And Vascular Companyreportable segment | employees | at 2026-03-31 | 2128 pure |
| Medical Care Solutions Companyreportable segment | employees | at 2026-03-31 | 2469 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,844
| Item | Context | Value | Unit |
|---|---|---|---|
| Capital expenditures IFRS | Prior1YearDuration_ReportableSegmentsMember | 79849000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_ReconcilingItemsMember | 2634000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration | 82484000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 676421000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 216138000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 231037000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000TerumoOrganTechnologiesReportableSegmentMember | 7985000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_ReportableSegmentsMember | 1131582000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_ReconcilingItemsMember | 294000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration | 1131877000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 163994000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 21568000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 33635000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000TerumoOrganTechnologiesReportableSegmentMember | 1665000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_ReportableSegmentsMember | 220864000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_ReconcilingItemsMember | -1494000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration | 219369000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -10723000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | -7000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -11090000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000TerumoOrganTechnologiesReportableSegmentMember | -2507000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_ReportableSegmentsMember | -24328000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration_ReconcilingItemsMember | 108000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYearDuration | -24220000000 | JPY |
| Non recurring profit or loss IFRS | CurrentYearDuration | -18828000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration | 176320000000 | JPY |
| Finance income IFRS | CurrentYearDuration | 6248000000 | JPY |
| Finance costs IFRS | CurrentYearDuration | 3286000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration | -1029000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 178252000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 45578000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 22588000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 25331000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000TerumoOrganTechnologiesReportableSegmentMember | 2766000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_ReportableSegmentsMember | 96265000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration_ReconcilingItemsMember | -885000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYearDuration | 95379000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 36719000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 36685000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 21700000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000TerumoOrganTechnologiesReportableSegmentMember | 1078000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_ReportableSegmentsMember | 96184000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration_ReconcilingItemsMember | 924000000 | JPY |
| Capital expenditures IFRS | CurrentYearDuration | 97108000000 | JPY |
| Merchandise and finished goods ca IFRS | Prior1YearInstant | 177525000000 | JPY |
| Merchandise and finished goods ca IFRS | CurrentYearInstant | 210237000000 | JPY |
| Work in process ca IFRS | Prior1YearInstant | 33342000000 | JPY |
| Work in process ca IFRS | CurrentYearInstant | 40154000000 | JPY |
| Raw materials and others ca IFRS | Prior1YearInstant | 83517000000 | JPY |
| Raw materials and others ca IFRS | CurrentYearInstant | 85243000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |